High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma

go back to reference Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS (2017) Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171(2):481–494.e15. https://doi.org/10.1016/j.cell.2017.09.027 CrossRefPubMed Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS (2017) Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171(2):481–494.e15. https://​doi.​org/​10.​1016/​j.​cell.​2017.​09.​027 CrossRefPubMed

go back to reference Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186(12):6905–6913. https://doi.org/10.4049/jimmunol.1100274 CrossRefPubMedPubMedCentral Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186(12):6905–6913. https://​doi.​org/​10.​4049/​jimmunol.​1100274 CrossRefPubMedPubMedCentral

go back to reference Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034. https://doi.org/10.1084/jem.192.7.1027 CrossRefPubMedPubMedCentral Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034. https://​doi.​org/​10.​1084/​jem.​192.​7.​1027 CrossRefPubMedPubMedCentral

go back to reference Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690 CrossRefPubMedPubMedCentral Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://​doi.​org/​10.​1056/​NEJMoa1200690 CrossRefPubMedPubMedCentral

go back to reference Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus associated malignancies. Clin Cancer Res 19(13):3462–3473. https://doi.org/10.1158/1078-0432.CCR-13-0855 CrossRefPubMedPubMedCentral Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus associated malignancies. Clin Cancer Res 19(13):3462–3473. https://​doi.​org/​10.​1158/​1078-0432.​CCR-13-0855 CrossRefPubMedPubMedCentral

go back to reference Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G et al (2014) High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 28(12):2367–2375. https://doi.org/10.1038/leu.2014.137 CrossRefPubMed Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G et al (2014) High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 28(12):2367–2375. https://​doi.​org/​10.​1038/​leu.​2014.​137 CrossRefPubMed

go back to reference Imawari Y, Mimoto R, Hirooka S, Morikawa T, Takeyama H, Yoshida K (2017) Downregulation of DYRK2 promotes tumor cell proliferation and invasion by enhancing CDK14 expression in breast cancer. Cancer Sci. https://doi.org/10.1111/cas.13459 Imawari Y, Mimoto R, Hirooka S, Morikawa T, Takeyama H, Yoshida K (2017) Downregulation of DYRK2 promotes tumor cell proliferation and invasion by enhancing CDK14 expression in breast cancer. Cancer Sci. https://​doi.​org/​10.​1111/​cas.​13459

go back to reference Huang R, Zhang D, Li F, Xiao Z, Wu M, Shi D, Xiang P, Bao Z (2017) Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells. Oncol Lett 13(5):3379–3386. https://doi.org/10.3892/ol.2017.5891 CrossRefPubMedPubMedCentral Huang R, Zhang D, Li F, Xiao Z, Wu M, Shi D, Xiang P, Bao Z (2017) Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells. Oncol Lett 13(5):3379–3386. https://​doi.​org/​10.​3892/​ol.​2017.​5891 CrossRefPubMedPubMedCentral

go back to reference Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P (2016) FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood 127(6):739–748. https://doi.org/10.1182/blood-2015-06-654111 CrossRefPubMed Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P (2016) FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood 127(6):739–748. https://​doi.​org/​10.​1182/​blood-2015-06-654111 CrossRefPubMed

go back to reference Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK (2015) MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget 6(17):15035–15049. https://doi.org/10.18632/oncotarget.3729 CrossRefPubMedPubMedCentral Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK (2015) MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget 6(17):15035–15049. https://​doi.​org/​10.​18632/​oncotarget.​3729 CrossRefPubMedPubMedCentral

go back to reference Weiskopf K, Anderson KL, Ito D, Schnorr PJ, Tomiyasu H, Ring AM, Bloink K, Efe J, Rue S, Lowery D, Barkal A, Prohaska S, McKenna KM, Cornax I, O'Brien TD, O'Sullivan MG, Weissman IL, Modiano JF (2016) Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20. Cancer Immunol Res 4(12):1072–1087. https://doi.org/10.1158/2326-6066.CIR-16-0105 CrossRefPubMedPubMedCentral Weiskopf K, Anderson KL, Ito D, Schnorr PJ, Tomiyasu H, Ring AM, Bloink K, Efe J, Rue S, Lowery D, Barkal A, Prohaska S, McKenna KM, Cornax I, O'Brien TD, O'Sullivan MG, Weissman IL, Modiano JF (2016) Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20. Cancer Immunol Res 4(12):1072–1087. https://​doi.​org/​10.​1158/​2326-6066.​CIR-16-0105 CrossRefPubMedPubMedCentral

go back to reference Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19):2193–2201. https://doi.org/10.1182/blood-2015-02-629600 CrossRefPubMedPubMedCentral Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126(19):2193–2201. https://​doi.​org/​10.​1182/​blood-2015-02-629600 CrossRefPubMedPubMedCentral

go back to reference Hawkes EA, Grigg A, Chong G (2015) Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 16(5):e234–e245. https://doi.org/10.1016/S1470-2045(15)70103-8 CrossRefPubMed Hawkes EA, Grigg A, Chong G (2015) Programmed cell death-1 inhibition in lymphoma. Lancet Oncol 16(5):e234–e245. https://​doi.​org/​10.​1016/​S1470-2045(15)70103-8 CrossRefPubMed